FINAL PROGRAM - Society for Immunotherapy of Cancer

Poster Listings
80
THE POST-PROLINE CLEAVING ENZYME INHIBITOR
4175 IS A NOVEL IMMUNOTHERAPEUTIC
ADJUVANT
Brynn Duncan 1 , Sarah Poplawski 2,3 , Paul Everill 2 , Barry Jones 2,3 ,
Wengen Wu 2 , Pen Zhao 2 , Youhua Li 2 , Yuxin Liu 2 , Gengli Yu 2 , Iwona
Woznica 2 , Jack H. Lai 2,3 , Bill Bachovchin 2,3 , Terry Fry 1
1
Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
2
Department of Biochemistry, Tufts University School of Medicine,
Boston, MA
3
Arisaph Pharmaceuticals, Boston, MA
81
IFN-ALPHA INCREASESTHE CYTOTOXIC EFFECT
OF CIK CELLS ON B-ALL
Ludovic Durrieu 1 , Joëlle Gregoire-Gauthier 1 , Mame Massar Dieng 1 ,
François Fontaine 1 , Françoise Le Deist 1,2,3 , Elie Haddad 1,2,3
1
Research Center of CHU Sainte-Justine, Montreal, QC, Canada
2
Microbiology and Immunology, University of Montreal, Montreal, QC,
Canada
3
Paediatrics, University of Montreal, Montreal, QC, Canada
82
INNATE IMMUNE ACTIVATION AND VACCINE
ADJUVANT POTENTIAL OFTLR-2 AGONIST, POLY
SACCHARIDE KRESTIN (PSK)
Abbi L. Engel 1,2 , Guan-Cheng Sun 2 , Ekram Gad 2 , Lauren Rastetter 2 ,
Cynthia Wenner 1 , Hailing Lu 2
1
Research Department, Bastyr University, Kenmore, WA
2
Tumor Vaccine Group, Center for Translational Medicine in Women’s
Health, University of Washington, Seattle, WA
83
WITHDRAWN BY AUTHOR
84
RADIATION AND ENDOPLASMIC RETICULUM
STRESS-INDUCER PROMOTE CALRETICULIN
TRANSLOCATION, CONTRIBUTING TO
IMMUNOGENIC CELL DEATH OF CANCER CELLS
Encouse Golden, Sandra Demaria, Mary Helen Barcellos-Hoff, Silvia
C. Formenti
New York University School of Medicine, New York, NY
85
HSP90 INHIBITORS ENHANCE IMMUNOLOGICAL
TARGETING OF MELANOMAS
Timothy J. Haggerty 1,2 , Ian S. Dunn 2 , Lenora B. Rose 2 , Estelle E.
Newton 2 , Franco Pandolfi 3 , James T. Kurnick 1,2
1
Pathology, Massachusetts General Hospital, Boston, MA
2
CytoCure LLC, Beverly, MA
3
Medicine, Catholic University, Roma, Italy
86
RNACTIVE VACCINES PROVIDE STRONG ANTI-
TUMOR EFFECT ESPECIALLY IN COMBINATION
WITH ANTI-CTLA4 THERAPY OR RADIATION
Kai Zanzinger 1 , Regina Heidenreich 1 , Mariola Fotin-Mleczek 1 ,
Christina Lorenz 1 , Stephan Huber 2 , Karl-Josef Kallen 1
1
CureVac GmbH, Tuebingen, Germany
2
Radiooncology, University Hospital, Tuebingen, Germany
87
IDO PEPTIDE VACCINATIONTRIAL FOR PATIENTS
WITH METASTATIC NON SMALL-CELL LUNG
CANCER. A FIRST-IN-MAN PHASE ITRIAL
(NCT01219348)
Trine Z. Iversen, Lotte Engell-Noerregaard, Eva Ellebaek, Bente
Holm, Anders Mellemgaard, Per T. Straten, Mads H. Andersen, Inge
Marie Svane
Department of Haematology and Oncology, Center for Cancer
Immune Therapy, University Hospital Herlev, Denmark
88
DIFFERENTIAL RESPONSESTO IMMUNOTHERAPY
OF ORTHOTOPICTUMORS COMPARED TO
SUBCUTANEOUSTUMORS
Christel Devaud, Jennifer A. Westwood, Connie P. Duong, Phillip K.
Darcy, Michael H. Kershaw
Cancer Immunotherapy Research Laboratory, Peter MacCallum Cancer
Center, Melbourne, VIC, Australia
89
DOCETAXEL ENHANCESTHE EFFICACY OF DC
IMMUNOTHERAPY BY REDUCING MYELOID
DERIVED SUPPRESSOR CELLS IN MELANOMA
MODEL
Krithika N. Kodumudi, Amy Mackay, Shari Pilon-Thomas
Department of Immunology, H. Lee Moffitt Cancer Center and
Research Institute, Tampa, FL
90
ENHANCED EXPRESSION OF CANCER-TESTIS
ANTIGENS IN PROSTATE CANCER CELL LINES
TREATED WITH EPIGENETIC MODIFYING AGENTS
Joshua M. Lang, Stephanie Thiede, Brianna Byers, Douglas G.
McNeel
Department of Medicine, Division of Hematology/Oncology, University
of Wisconsin, Madison, WI
66
FINAL PROGRAM • SITC 26 TH ANNUAL MEETING
November 4-6, 2011 • North Bethesda, MD • www.sitcancer.org